92 related articles for article (PubMed ID: 16623634)
1. Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients.
Bonjoch A; Paredes R; Domingo P; Cervantes M; Pedrol E; Ribera E; Force L; Llibre JM; Vilaró J; Dalmau D; Cucurull J; Mascaró J; Masabeu A; Pérez-Alvarez N; Puig J; Cinquegrana D; Clotet B
AIDS Res Hum Retroviruses; 2006 Apr; 22(4):321-9. PubMed ID: 16623634
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
Gil P; de Górgolas M; Estrada V; Arranz A; Rivas P; Yera C; García R; Granizo JJ; Fernández-Guerrero M
Clin Infect Dis; 2004 Oct; 39(7):1024-9. PubMed ID: 15472856
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
[TBL] [Abstract][Full Text] [Related]
5. Long-term follow-up of nevirapine-treated patients in a single-centre cohort.
Colafigli M; Di Giambenedetto S; Bracciale L; Fanti I; Prosperi M; Cauda R; De Luca A
HIV Med; 2009 Sep; 10(8):461-9. PubMed ID: 19459991
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
Zhou HY; Zheng YH; He Y; Chen Z; Liu M; Yin W; Liu C
Intervirology; 2010; 53(4):240-6. PubMed ID: 20357493
[TBL] [Abstract][Full Text] [Related]
7. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
[TBL] [Abstract][Full Text] [Related]
8. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.
Barreiro P; Soriano V; Blanco F; Casimiro C; de la Cruz JJ; González-Lahoz J
AIDS; 2000 May; 14(7):807-12. PubMed ID: 10839588
[TBL] [Abstract][Full Text] [Related]
9. Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
Reliquet V; Allavena C; François-Brunet C; Perré P; Bellein V; Garré M; May T; Souala F; Besnier JM; Raffi F
HIV Med; 2006 Oct; 7(7):431-6. PubMed ID: 16925728
[TBL] [Abstract][Full Text] [Related]
10. Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine.
Rodríguez-Arrondo F; Aguirrebengoa K; Portu J; Muñoz J; García MA; Goikoetxea J; Martínez E; Iribarren JA; Perez-Alvarez N; Negredo E; Clotet B
Curr HIV Res; 2009 Sep; 7(5):526-32. PubMed ID: 19925403
[TBL] [Abstract][Full Text] [Related]
11. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
Gathe J; Andrade-Villanueva J; Santiago S; Horban A; Nelson M; Cahn P; Bogner J; Spencer D; Podzamczer D; Yong CL; Nguyen T; Zhang W; Drulak M; Quinson AM
Antivir Ther; 2011; 16(5):759-69. PubMed ID: 21817198
[TBL] [Abstract][Full Text] [Related]
14. Twelve-year experience of nevirapine use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients.
Reliquet V; Allavena C; Morineau-Le Houssine P; Mounoury O; Raffi F
HIV Clin Trials; 2010; 11(2):110-7. PubMed ID: 20542847
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
16. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
[TBL] [Abstract][Full Text] [Related]
17. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.
Keiser P; Nassar N; White C; Koen G; Moreno S
HIV Clin Trials; 2002; 3(4):296-303. PubMed ID: 12187503
[TBL] [Abstract][Full Text] [Related]
18. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients.
de Beaudrap P; Etard JF; Guèye FN; Guèye M; Landman R; Girard PM; Sow PS; Ndoye I; Delaporte E;
AIDS Res Hum Retroviruses; 2008 Jun; 24(6):753-60. PubMed ID: 18507521
[TBL] [Abstract][Full Text] [Related]
20. [Favorable new data for nevirapine. Antiretroviral effect confirmed--and also lipid profile].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():58-60. PubMed ID: 15373051
[No Abstract] [Full Text] [Related]
[Next] [New Search]
